BioNTech continues to confirm its role as a leading bio-tech pioneer showing promising data with their cancer drugs and vaccines. Their bispecific antibody
PD-L1/VEGF has been creating a stir in the bio-tech world with exciting results from
triple negative breast cancer trials. The
US FDA also lifted a hold on the clinical study of a BioNTech's cancer drug, suggesting potential advancement in treatment strategies. The
Oncology strategy of BioNTech is being backed by a new acquisition, Biotheus, giving them more control of vital cancer drugs. With the expansion of their partnership with
CEPI, BioNTech is planning to strengthen Africa’s mRNA vaccine ecosystem as well. Concurrently, BioNTech has initiated trials of the lung cancer vaccine using
mRNA technology. However, amidst these advancements, BioNTech faced a setback with the attempt in developing a combined influenza and COVID-19 vaccine. Lower than expected demand for the Pfizer-partnered COVID-19 vaccine led to increased focus and R&D spending on oncology drugs.
BIONTECH News Analytics from Wed, 20 Mar 2024 07:00:00 GMT to Sat, 14 Dec 2024 12:31:51 GMT -
Rating 5
- Innovation 7
- Information 8
- Rumor -3
